PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus

Modern Pathology

Volumn 23, Issue 4, 2010, Pages 593-602

  Feldman, Andrew L ^a   Law, Mark E ^a   Inwards, David J ^a   Dogan, Ahmet ^a   McClure, Rebecca F ^a   MacOn, William R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anaplastic large cell lymphoma; CD30; FISH; Hodgkin's lymphoma; Immunohistochemistry; PAX5

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; TRANSCRIPTION FACTOR PAX5; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HUMAN; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN TRANSPORT; T CELL LYMPHOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; B-CELL-SPECIFIC ACTIVATOR PROTEIN; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 77950518000     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.4     Document Type: Article

References (53)

1. Swerdlow S, Campo E, Harris N, et al (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman F, Jaffe E, Lakhani S, Ohgaki H (eds), World Health Organization Classification of Tumours, 4th edn. International Agency for Research on Cancer: Lyon, 2008.
2. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96: 3681-3695.
3. Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases. Am J Surg Pathol 2006;30:223-229. (Pubitemid 43740192)
4. Leoncini L, Del Vecchio M, Kraft R, et al. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas-a continuous spectrum of malignant disorders. Am J Pathol 1990;137:1047-1057.
5. Pileri S, Bocchia M, Baroni C, et al. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinicopathologic study of 69 cases. Br J Haematol 1994;86:513-523. (Pubitemid 24199039)
6. Stein H, Delsol G, Pileri SA, et al. Classical Hodgkin lymphoma, introduction. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, 2008, pp 326-329.
7. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219-228. (Pubitemid 32246828)
8. Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer: Lyon, 2008, pp 317-319.
9. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol 2005;18:1542-1549. (Pubitemid 41670652)
10. Asano N, Oshiro A, Matsuo K, et al. Prognostic significance of T-cell or cytotoxic molecules pheno-type in classical Hodgkin's lymphoma: a clinicopatho-logic study. J Clin Oncol 2006;24:4626-4633. (Pubitemid 46630961)
11. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003;27:1513-1522. (Pubitemid 37486612)
12. Felgar RE, Salhany KE, Macon WR, et al. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol 1999;30:228-236.
13. Gorczyca W, Tsang P, Liu Z, et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohisto-chemical analysis. Int J Oncol 2003;22:319-324.
14. Perkins PL, Ross CW, Schnitzer B. CD30-positive, anaplastic large-cell lymphomas that express CD15 but lack CD45. A possible diagnostic pitfall. Arch Pathol Lab Med 1992;116:1192-1196.
15. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996;88:4005-4011. (Pubitemid 26383125)
16. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004;104:3358-3360. (Pubitemid 39507158)
17. Quintanilla-Martinez L, Preffer F, Rubin D, et al. CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol 1994;102: 483-489. (Pubitemid 24323344)
18. Blakolmer K, Vesely M, Kummer JA, et al. Immunor-eactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T-(NK/T-) cell lym-phomas. Mod Pathol 2000;13:766-772. (Pubitemid 30470166)
19. Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol 2001;14: 105-110. (Pubitemid 32173393)
20. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24:2472-2479. (Pubitemid 46630624)
21. Sen F, Kang S, Cangiarella J, et al. CD20 positive mycosis fungoides: a case report. J Cutan Pathol 2008; 35:398-403. (Pubitemid 351363763)
22. Wellmann A, Otsuki T, Vogelbruch M, et al. Analysis of the t(2;5) (p23;q35) translocation by reverse tran-scription-polymerase chain reaction in CD 30+ ana-plastic large-cell lymphomas, in other non-Hodgkin's of T-cell phenotype, and in Hodgkin's disease. Blood 1995;86:2321-2328.
23. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
24. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunopheno-typically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
25. Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:897-914. (Pubitemid 47484141)
26. Nutt SL, Heavey B, Rolink AG, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999;401:556-562. (Pubitemid 129517063)
27. Mikkola I, Heavey B, Horcher M, et al. Reversion of B cell commitment upon loss of Pax5 expression. Science 2002;297:110-113. (Pubitemid 34743105)
28. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007;449:473-477. (Pubitemid 47509547)
29. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumors: a high-throughput tissue microarray analysis. J Clin Pathol 2007;60:709-714. (Pubitemid 46975231)
30. Feldman AL, Dogan A. Diagnostic uses of Pax5 immuno-histochemistry. Adv Anat Pathol 2007;14:323-334.
31. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92: 1308-1316. (Pubitemid 28369044)
32. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
33. Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 2004;64:7399-7404. (Pubitemid 39372080)
34. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94: 3108-3113. (Pubitemid 29512717)
35. Kurtin PJ, Hobday KS, Ziesmer S, et al. Demonstration of distinct antigenic profiles of small B-cell lympho-mas by paraffin section immunohistochemistry. Am J Clin Pathol 1999;112:319-329. (Pubitemid 30214770)
36. Morice WG, Katzmann JA, Pittelkow MR, et al. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol 2006;125: 364-374.
37. McClure RF, Kaur P, Pagel E, et al. Validation of immunoglobulin gene rearrangement detection by PCR using commercially available BIOMED-2 primers. Leukemia 2006;20:176-179.
38. Remstein ED, Law M, Mollejo M, et al. The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia 2007;22: 1268-1272.
39. Feldman AL, Law M, Grogg KL, et al. Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. Am J Clin Pathol 2008;130: 178-185.
40. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91:2076-2084. (Pubitemid 28185511)
41. Walther C, Guenet JL, Simon D, et al. Pax: a murine multigene family of paired box-containing genes. Genomics 1991;11:424-434.
42. Tan BT, Seo K, Warnke RA, et al. The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK-anaplastic large cell lympho-ma and other peripheral T-cell lymphomas. J Mol Diagn 2008;10:502-512.
43. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004; 202:60-69. (Pubitemid 38072846)
44. Tamaru J, Tokuhira M, Nittsu N, et al. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunopheno-typic features to classical Hodgkin lymphoma. Leuk Lymphoma 2007;48:1127-1138. (Pubitemid 47009203)
45. Tzankov AS, Went PT, Munst S, et al. Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol 2007;20:632-637. (Pubitemid 46795145)
46. Busslinger M, Klix N, Pfeffer P, et al. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 1996;93:6129-6134. (Pubitemid 26190815)
47. Poppe B, De Paepe P, Michaux L, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005;44:218-223. (Pubitemid 41306651)
48. Souabni A, Jochum W, Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood 2007;109:281-289. (Pubitemid 46053068)
49. Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008;140:516-526. (Pubitemid 351230071)
50. Mao X, Orchard G, Lillington DM, et al. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003;37:176-185. (Pubitemid 36529785)
51. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164:1837-1848. (Pubitemid 38529786)
52. Lazzi S, Bellan C, Onnis A, et al. Rare lymphoid neoplasms coexpressing B-and T-cell antigens. The role of PAX-5 gene methylation in their pathogenesis. Hum Pathol 2009;40:1252-1261.
53. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003;63:4620-4625.